No. 3: Medivation ( MDVN)

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

One day, Medivation shares are up 9% for the year. Twenty-four hours later, Medivation is up 162%. This sudden and spectacular jump in market value -- akin to winning the lottery -- is what makes biotech stocks irresistible for so many investors. Medivation's spark was the November announcement of a successful phase III study for its prostate cancer drug MDV3100.

The stock: Medivation shares weren't done moving higher after that very good, early November day. As of Dec. 16, Medivation is up 199% for the year.

If you liked this article you might like

Johnson & Johnson Looks for New Deal That's Just Right

The Nominees for Best Biopharma CEO of 2015 Are...

Jim Cramer's 'Mad Money' Recap: Here's How Oil, the Fed and China Pushed Markets Up

AXON, REGN, BURL, FIVE: Jim Cramer's Views

The 10 Biggest U.S. M&A Deals in 2015